Christopher H. Crane mostly deals with Surgery, Radiation therapy, Internal medicine, Pancreatic cancer and Chemoradiotherapy. His studies in Surgery integrate themes in fields like Cancer, Colorectal cancer, Primary tumor and Radiology. His Radiation therapy research integrates issues from Fluorouracil, Chemotherapy, Rectum, Capecitabine and Survival analysis.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology. His study looks at the relationship between Pancreatic cancer and fields such as Pancreatectomy, as well as how they intersect with chemical problems. His Adenocarcinoma research includes themes of Combined Modality Therapy, Surgical oncology and Pancreatic disease.
His primary areas of study are Internal medicine, Radiation therapy, Oncology, Surgery and Pancreatic cancer. His work on Gemcitabine, Adenocarcinoma and Capecitabine as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines. His Radiation therapy research incorporates elements of Nuclear medicine, Anal cancer and Chemotherapy.
His work in Oncology tackles topics such as Carcinoma which are related to areas like Survival rate. His studies in Surgery integrate themes in fields like Neoadjuvant therapy and Cancer, Colorectal cancer. His studies deal with areas such as Pancreatectomy, Pancreatic disease and Clinical trial as well as Pancreatic cancer.
Christopher H. Crane mainly focuses on Internal medicine, Oncology, Radiation therapy, Radiology and Surgery. His research ties Gastroenterology and Internal medicine together. Christopher H. Crane has researched Oncology in several fields, including Survival rate, Cancer, Esophageal cancer and CA19-9.
His biological study spans a wide range of topics, including Proportional hazards model, Intrahepatic Cholangiocarcinoma, Chemotherapy and Nuclear medicine. His Radiology research includes elements of Prospective cohort study and Anal Squamous Cell Carcinoma. His Surgery study combines topics from a wide range of disciplines, such as Recurrent Rectal Cancer, Colorectal cancer, Anal cancer and Toxicity.
Internal medicine, Oncology, Radiation therapy, Surgery and Carcinoma are his primary areas of study. His study in Gemcitabine, Pancreatic cancer, Chemoradiotherapy, Capecitabine and Odds ratio falls under the purview of Internal medicine. His Oncology research integrates issues from Survival rate, Cancer, Adenocarcinoma and Pancreatectomy.
His Survival rate study integrates concerns from other disciplines, such as Neoadjuvant therapy, Combined Modality Therapy, Phases of clinical research and Lymph node. His Radiation therapy research includes themes of Medical physics, Proportional hazards model and Nuclear medicine. His Surgery study frequently involves adjacent topics like Recurrent Rectal Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong.
Annals of Surgical Oncology (2006)
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun.
Journal of The American College of Surgeons (2008)
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner.
Journal of Clinical Oncology (2011)
Pancreaticoduodenectomy with vascular resection: margin status and survival duration
Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters.
Journal of Gastrointestinal Surgery (2004)
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang.
Annals of Surgery (2007)
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun.
Annals of Surgical Oncology (2009)
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
T. M. Breslin;K. R. Hess;D. B. Harbison;M. E. Jean.
Annals of Surgical Oncology (2001)
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response
Jaffer A. Ajani;Kathryn Winter;Gordon S. Okawara;John H. Donohue.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Medical College of Wisconsin
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Duke University
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
University of Edinburgh
University of Vienna
Cornell University
Kyoto University
University of Freiburg
Stockholm University
Imperial College London
University of Southampton
University of Auckland
Fox Chase Cancer Center
University of Illinois at Urbana-Champaign
The University of Texas Medical Branch at Galveston
University of New South Wales
Vanderbilt University
University of California, Berkeley